The prostacyclin pathway in pulmonary arterial hypertension: a clinical review

References

• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Shah SJ, Souza R, et al. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976–1997.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–1030.
   PubMed Web of Science ®Google Scholar
• Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012;186(8):790–796.
   PubMed Web of Science ®Google Scholar
• Escribano-Subias P, Blanco I, López-Meseguer M, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40(3):596–603.
   PubMed Web of Science ®Google Scholar
• Jansa P, Jarkovsky J, Al-Hiti H, et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med. 2014;14:45.
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12Suppl S):13S–24S.
   PubMed Web of Science ®Google Scholar
• Clapp LH, Gurung R. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat. 2015;120:56–71.
   PubMed Web of Science ®Google Scholar
• Humbert M, Ghofrani HA. The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax. 2016;71(1):73–83.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–975.
   PubMed Web of Science ®Google Scholar
• Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D60–72.
   PubMed Web of Science ®Google Scholar
• Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146(2):449–475.
   PubMed Web of Science ®Google Scholar
• Alfranca A, Iñiguez MA, Fresno M, et al. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc Res. 2006;70(3):446–456.
   PubMed Web of Science ®Google Scholar
• Vane J, Corin RE. Prostacyclin: a vascular mediator. Eur J Vasc Endovasc Surg. 2003;26(6):571–578.
   PubMed Web of Science ®Google Scholar
• Kothapalli D, Stewart SA, Smyth EM, et al. Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. Mol Pharmacol. 2003;64(2):249–258.
   PubMed Web of Science ®Google Scholar
• Weiss HJ, Turitto VT. Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood. 1979;53(2):244–250.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159(6):1925–1932.
   PubMed Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70–75.
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Noda K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther. 2008;326(3):691–699.
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007;322(3):1181–1188.
   PubMed Web of Science ®Google Scholar
• Lang IM, Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev. 2015;24(138):630–641.
   PubMedGoogle Scholar
• Richter MJ, Gall H, Grimminger J, et al. Selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2016;17(13):1825–1834.
   PubMed Web of Science ®Google Scholar
• Whittle BJ, Silverstein AM, Mottola DM, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012;84(1):68–75.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982;66(2):334–338.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301.
   PubMed Web of Science ®Google Scholar
• Saito Y, Nakamura K, Akagi S, et al. Epoprostenol sodium for treatment of pulmonary arterial hypertension. Vasc Health Risk Manag. 2015;11:265–270.
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, McLaughlin V, Gulati M, et al. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol. 2005;96(9):1334–1336.
   PubMed Web of Science ®Google Scholar
• Flolan® EMA Summary of product characteristics [Internet]. [ cited 2016 Nov 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/flolan_30/WC500129816.pdf
   Google Scholar
• Sitbon O, Delcroix M, Bergot E, et al. EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J. 2014;167(2):210–217.
   PubMed Web of Science ®Google Scholar
• Wade M, Baker FJ, Roscigno R, et al. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. J Clin Pharmacol. 2004;44(5):503–509.
   PubMed Web of Science ®Google Scholar
• Remodulin® (Treprostinil sodium) Injection product information[Internet]. [ cited 2017 Feb 2]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021272s009lbl.pdf
   Google Scholar
• Burger CD, D’Albini L, Raspa S, et al. The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management. Am J Manag Care. 2016;22(1 Suppl):S3–S15.
   PubMed Web of Science ®Google Scholar
• Olschewski H, Rohde B, Behr J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest. 2003;124(4):1294–1304.
   PubMed Web of Science ®Google Scholar
• Hill NS, Preston IR, Roberts KE. Inhaled therapies for pulmonary hypertension. Respir Care. 2015;60(6):794–802.
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(12):2119–2125.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. US National Institutes of Health. Beraprost-314d Added-on to Tyvaso® (BEAT). [ cited 2016 Nov 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT01908699?term=NCT01908699&rank=1
   Google Scholar
• Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624–633.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Torbicki A, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874–880.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112(7):485–491.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425–434.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521–530.
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353–359.
   PubMed Web of Science ®Google Scholar
• Badesch DB, McGoon MD, Barst RJ, et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009;36(10):2244–2249.
   PubMed Web of Science ®Google Scholar
• Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003;167(4):580–586.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477–1482.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–788.
   PubMed Web of Science ®Google Scholar
• Kitterman N, Poms A, Miller DP, et al. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®. Mayo Clin Proc. 2012;87(9):825–834.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39(9):1496–1502.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34(4):1188–1192.
   PubMed Web of Science ®Google Scholar
• Sakao S, Tanabe N, Kasahara Y, et al. Long-term survival of Japanese patients with pulmonary arterial hypertension treated with beraprost sodium, an oral prostacyclin analogue. Intern Med. 2014;53(17):1913–1920.
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–329.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28(4):691–694.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257–1263.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342(25):1866–1870.
   PubMed Web of Science ®Google Scholar
• Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010;104(5):731–740.
   PubMed Web of Science ®Google Scholar
• Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26(18):1895–1902.
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Mainwood A, Morrell NW, et al. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. Pulm Pharmacol Ther. 2011;24(1):169–173.
   PubMed Web of Science ®Google Scholar
• Higenbottam TW, Butt AY, Dinh-Xaun AT, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart. 1998;79(2):175–179.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J. 2009;34(1):132–137.
   PubMed Web of Science ®Google Scholar
• Knudsen L, Schurawlew A, Nickel N, et al. Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. BMC Pulm Med. 2011;11:56.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41(2):293–299.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800–804.
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126(2):420–427.
   PubMed Web of Science ®Google Scholar
• Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29(2):137–149.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915–1922.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383–1390.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952–958.
   PubMed Web of Science ®Google Scholar
• Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129(6):1636–1643.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195–1203.
   PubMed Web of Science ®Google Scholar
• Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011;30(12):1327–1333.
   PubMed Web of Science ®Google Scholar
• Benza RL, Tapson VF, Gomberg-Maitland M, et al. One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J Heart Lung Transplant. 2013;32(9):889–896.
   PubMed Web of Science ®Google Scholar
• Chin KM, Ruggiero R, Bartolome S, et al. Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center. Pulm Circ. 2015;5(3):513–520.
   PubMed Web of Science ®Google Scholar
• White RJ, Levin Y, Wessman K, et al. Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. Pulm Circ. 2013;3(3):611–621.
   PubMed Web of Science ®Google Scholar
• Zamanian RT, Levine DJ, Bourge RC, et al. An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension. Pulm Circ. 2016;6(3):329–337.
   PubMed Web of Science ®Google Scholar
• Maron BA, Galiè N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: a review. JAMA Cardiol. 2016;1(9):1056–1065.
   PubMed Web of Science ®Google Scholar
• Madonna R, Cocco N. Novel strategies in the treatment of pulmonary arterial hypertension. Curr Drug Targets. 2016;17(7):817–823.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, McLaughlin VV, Dalaan AM, et al. Treatment of pulmonary hypertension. Lancet Respir Med. 2016;4(4):323–336.
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107(2):216–223.
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349.
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104–109.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156–163.
   PubMed Web of Science ®Google Scholar
• Jing Z-C, Xu X-Q, Han Z-Y, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007;132(2):373–379.
   PubMed Web of Science ®Google Scholar
• McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008;83(8):923–931.
   PubMed Web of Science ®Google Scholar
• Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest. 2011;139(1):128–137.
   PubMed Web of Science ®Google Scholar
• Lee WT, Ling Y, Sheares KK, et al. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J. 2012;40(3):604–611.
   PubMed Web of Science ®Google Scholar
• Jiang X, Humbert M, Jing ZC. Idiopathic pulmonary arterial hypertension and its prognosis in the modern management era in developed and developing countries. In: Humbert M, Souza R, Simonneau G, editors. Pulmonary Vascular Disorders. Prog Respir Res. Basel: Karger; 2012. p. 85–93.
   Google Scholar
• Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern management era. Chest. 2011;140(2):301–309.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013;168(2):871–880.
   PubMed Web of Science ®Google Scholar
• Pauwaa S, Machado RF, Desai AA. Survival in pulmonary arterial hypertension: a brief review of registry data. Pulm Circ. 2011;1(3):430–431.
   PubMedGoogle Scholar
• McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012;21(123):8–18.
   PubMedGoogle Scholar
• McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(25 Suppl):D51–D59.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–387.
   PubMed Web of Science ®Google Scholar
• Baptista R, Meireles J, Agapito A, et al. Pulmonary hypertension in Portugal: first data from a nationwide registry. Biomed Res Int. 2013;2013:489574.
   PubMed Web of Science ®Google Scholar
• Farber HW, Miller DP, Meltzer LA, et al. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant. 2013;32(11):1114–1122.
   PubMed Web of Science ®Google Scholar
• Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043–1054.
   PubMed Web of Science ®Google Scholar
• Bourge RC, Waxman AB, Gomberg-Maitland M, et al. Treprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system: results of the DelIVery for PAH trial. Chest. 2016;150(1):27–34.
   PubMed Web of Science ®Google Scholar
• Shaked A, Tenenbaum-Koren E, Atsmon J, et al. In vitro and in vivo performance of a pre-filled, electrochemically-actuated infusion system. Pharm Res. 2016;33(1):83–91.
   PubMed Web of Science ®Google Scholar
• Ishihara T, Hayashi E, Yamamoto S, et al. Encapsulation of beraprost sodium in nanoparticles: analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension. J Control Release. 2015;197:97–104.
   PubMed Web of Science ®Google Scholar
• Akagi S, Nakamura K, Matsubara H, et al. Intratracheal administration of prostacyclin analogue-incorporated nanoparticles ameliorates the development of monocrotaline and sugen-hypoxia-induced pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2016;67(4):290–298.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. US National Institutes of Health. Trial of the early combination of oral treprostinil with background oral monotherapy in subjects with pulmonary arterial hypertension (FREEDOM-Ev). [ cited 2016 Nov 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT01560624?term=freedom-ev&rank=1
   Google Scholar
• ClinicalTrials.gov [Internet]. US National Institutes of Health. ACT-293987 in pulmonary arterial hypertension. [ cited 2016 Nov 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01112306?term=selexipag&rank=11
   Google Scholar
• ClinicalTrials.gov [Internet]. US National Institutes of Health. The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension (TRITON). [ cited 2016 Nov 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02558231?term=selexipag&rank=12
   Google Scholar
• ClinicalTrials.gov [Internet]. US National Institutes of Health. Study to assess the tolerability and the safety of the transition from inhaled treprostinil to oral selexipag in patients with pulmonary arterial hypertension (TRANSIT-1). [ cited 2016 Nov 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02471183?term=selexipag&rank=8
   Google Scholar
• Galiè N, Barberà JA, Frost AE, et al. AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–844.
   PubMed Web of Science ®Google Scholar